# US 2026/0083753 A1 · Compositions for the Treatment of Metabolic Syndrome and Other Metabolic Disorders, and Methods of Manufacture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083753 A1
- Document ID: US20260083753A1
- Status: Published application
- Kind: A1
- Application number: 19/274,778
- Filed: 2025-07-21
- Published: 2026-03-26
- Earliest claimed: 2024-09-23
- Assignees: Florida Research Group LLC
- Applicants: Florida Research Group, LLC
- Inventors: Kotha SEKHARAM
- Web page: https://patentgrep.com/patent/US20260083753A1

## CPC

- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 9/146: {with organic macromolecular compounds}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject invention provides improved compositions for metabolic syndrome and methods of preparing the compositions via, for example, hot-melt extrusion. The resulting extrudate has improved solubility, bioavailability and therapeutic effect for treatment of metabolic syndrome at a low dose.

## Claims

### Claim 1

A method for preparing a composition for the treatment of a metabolic disorder, wherein the method comprises:
(i) blending (a) one or more of 3β-hydroxyurs-12-en-28-oic acid (UA), 3β-hydroxyolean-12-en-28-oic acid (OA), and salts thereof with (b) at least one modulator extract selected from the group consisting of piperine, capsaicin, and gingerol, and (c) a water-soluble polymer having a glass transition temperature lower than 170° C.;
(ii) melt extruding the blend at a temperature about 60° C. to about 180° C. to obtain an extrusion product;
(iii) grinding and mixing the extrusion product with a carrier or excipient to produce the composition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is free from any solvent.

### Claim 3 (depends on 1)

The method of claim 1, wherein UA and/or OA is in amorphous form in the composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the UA and/or OA is a component of a botanical extract.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one modulator extract is piperine of formula:

### Claim 6 (depends on 1)

The method of claim 1, wherein the water-soluble polymer is selected from the group consisting of polyvinyl caprolactam, polyvinyl acetate-polyethylene glycol graft copolymer, polyvinylpyrrolidone-vinyl acetate copolymer, polyethylene glycol, amino methacrylate copolymer, hypromellose acetate succinate and combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the water-soluble polymer is poly vinylpyrrolidonevinyl acetate copolymer.

### Claim 8 (depends on 1)

The method of claim 1, wherein UA and/or OA is about 1% to 50% of the weight of the composition.

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one modulator extract is about 0.1 to about 25% of the weight of the composition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the water-soluble polymer is about 5% to about 90% of the weight of the composition.

### Claim 11 (depends on 1)

The method of claim 1, wherein the blend of (i) is melted while it passes through at least four heating zones of an extruder, wherein a temperature of each heating zone is sequentially lowered.

### Claim 12

A pharmaceutical composition comprising:
(a) at least one of the following:
UA, an isomer, or a salt thereof; and
OA, an isomer or a salt thereof;
(b) at least one modulator extract selected from the group consisting of piperine, capsaicin, and gingerol;
(c) a water-soluble polymer having a glass transition temperature lower than 170° C.; and
(d) a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the UA is a compound of formula:

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the OA is a compound of formula:

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the at least one modulator extract is piperine of formula:

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the composition comprises a water-soluble polymer selected from the group consisting of polyvinyl caprolactam, polyvinyl acetate-polyethylene glycol graft copolymer, polyvinylpyrrolidone-vinyl acetate copolymer, polyethylene glycol, amino methacrylate copolymer, and hypromellose acetate succinate.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the water-soluble polymer is poly vinylpyrrolidonevinyl acetate copolymer.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein UA and/or OA is about 1% to 50% of the weight of the composition.

### Claim 19 (depends on 12)

The pharmaceutical composition of claim 12, wherein the at least one modulator extract is about 0.1 to about 25% of the weight of the composition.

### Claim 20 (depends on 12)

The pharmaceutical composition of claim 12, wherein the water-soluble polymer is about 5% to about 90% of the weight of the composition.

### Claim 21 (depends on 12)

The pharmaceutical composition of claim 12, which is in a form of a capsule, tablet, chewable tablet, soft chew, gummy, lozenge, bar, oral paste, suppository, powder, or an adjunct to food or feed.

### Claim 22 (depends on 12)

A method for treating a metabolic disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 12.

### Claim 23 (depends on 22)

The method of claim 22, wherein the subject is human.

### Claim 24 (depends on 22)

The method of claim 22, wherein the metabolic disorder is metabolic syndrome.

### Claim 25 (depends on 12)

A supplement comprising the pharmaceutical composition of claim 12.
